Catheter ablation reduces cardiovascular risk in atrial fibrillation with normal left atrial diameter but not in enlarged atria

This randomized controlled trial enrolled 1130 patients with atrial fibrillation who underwent echocardiographic measurement for left atrial diameter at baseline. The study population was derived from the CABANA trial, though the specific setting was not reported. Participants were randomized to receive either catheter ablation or drug therapy. The primary outcome was a composite of death, disabling stroke, serious bleeding, or cardiac arrest. Secondary outcomes included total mortality. The follow-up duration was not reported in the provided data.

The intervention involved catheter ablation, while the comparator was drug therapy. The absolute numbers showed that 570 patients (50.4%) were randomized to ablation and 560 patients (49.6%) to drug therapy. The analysis focused on how baseline left atrial diameter (LAD) modified the treatment effect. Patients were stratified into two groups based on LAD: those with LAD less than or equal to 40 mm and those with LAD greater than 40 mm.

Regarding the primary outcome, the adjusted hazard ratio for the composite endpoint was 0.30 (95% CI 0.11-0.78) in patients without enlarged LAD (LAD ≤ 40 mm). In contrast, the adjusted hazard ratio was 0.92 (95% CI 0.55-1.54) in patients with enlarged LAD (LAD > 40 mm). The interaction P-value was .035, indicating a statistically significant difference in treatment effect across the LAD subgroups. The direction of the effect showed that benefits declined as LAD increased.

For the secondary outcome of total mortality, the adjusted hazard ratio was 0.09 (95% CI 0.01-0.58) in patients without enlarged LAD (LAD ≤ 40 mm). In patients with enlarged LAD (LAD > 40 mm), the adjusted hazard ratio was 0.76 (95% CI 0.40-1.41). The interaction P-value for total mortality was .045. Absolute numbers for mortality were not reported. Similar to the primary outcome, the benefits of ablation over drug therapy declined substantially as LAD increased.

Safety and tolerability findings, including adverse event rates, serious adverse events, discontinuations, and general tolerability, were not reported in the provided data. Consequently, a detailed assessment of the safety profile cannot be made based on this specific dataset. Funding sources and potential conflicts of interest were not reported.

The study design and results highlight a critical interaction between anatomical substrate and treatment efficacy. In patients with normal left atrial dimensions, ablation demonstrated a robust reduction in cardiovascular risk compared to drug therapy. However, in patients with enlarged left atria, the magnitude of benefit was substantially reduced, approaching null in some metrics. This suggests that the degree of atrial remodeling is a key determinant of whether ablation provides a survival or morbidity advantage over standard pharmacologic management.

Comparisons to prior landmark studies in this therapeutic area are limited by the specific stratification by LAD presented here. The results imply that early rhythm control strategies may be most effective before significant structural remodeling occurs. Methodological limitations include the lack of reported safety data and the absence of specific setting details. Potential biases related to the selection of patients with varying degrees of atrial enlargement were not explicitly detailed in the provided text.

Clinical implications suggest that clinicians should consider baseline left atrial diameter when counseling patients about the potential benefits of catheter ablation versus drug therapy. Ablation appears to be an effective early rhythm control strategy to reduce cardiovascular risk specifically in the lowest end of the LAD spectrum. For patients with enlarged atria, the data indicates that the incremental benefit of ablation over drugs is less clear. Further questions remain regarding the optimal timing of ablation relative to the progression of atrial remodeling and whether other structural markers might predict response to ablation.